Stock Yards Bank & Trust Co. Has $293,000 Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Stock Yards Bank & Trust Co. lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 9.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 2,713 shares of the medical equipment provider’s stock after selling 267 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Zimmer Biomet were worth $293,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in ZBH. American Century Companies Inc. raised its stake in shares of Zimmer Biomet by 12.6% in the second quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider’s stock valued at $701,521,000 after purchasing an additional 722,041 shares in the last quarter. Equity Investment Corp acquired a new position in shares of Zimmer Biomet in the 3rd quarter valued at $70,104,000. Hotchkis & Wiley Capital Management LLC boosted its position in shares of Zimmer Biomet by 49.1% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock valued at $189,161,000 after acquiring an additional 577,320 shares in the last quarter. Magnetar Financial LLC increased its stake in Zimmer Biomet by 58.7% in the second quarter. Magnetar Financial LLC now owns 1,310,265 shares of the medical equipment provider’s stock valued at $142,203,000 after acquiring an additional 484,816 shares during the period. Finally, Van ECK Associates Corp raised its position in Zimmer Biomet by 12.4% in the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock worth $391,239,000 after purchasing an additional 411,163 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ZBH has been the topic of several recent analyst reports. Canaccord Genuity Group reduced their target price on shares of Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, September 10th. Royal Bank of Canada raised their target price on Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research note on Monday, November 4th. Raymond James reduced their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Wells Fargo & Company upped their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Finally, Wolfe Research assumed coverage on shares of Zimmer Biomet in a report on Tuesday, September 10th. They issued a “peer perform” rating for the company. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $122.83.

Zimmer Biomet Stock Down 0.1 %

ZBH stock opened at $106.74 on Friday. Zimmer Biomet Holdings, Inc. has a 52 week low of $101.47 and a 52 week high of $133.90. The business has a 50-day simple moving average of $107.69 and a 200 day simple moving average of $108.75. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The company has a market cap of $21.25 billion, a PE ratio of 20.29, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same quarter in the previous year, the firm earned $1.65 EPS. Zimmer Biomet’s revenue was up 4.1% on a year-over-year basis. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.